- Home
- BMEA vs CABA Comparison
BMEA vs CABA Comparison
Compare BMEA & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- CABA
- Stock Information
- Founded
- BMEA 2017
- CABA 2017
- Country
- BMEA United States
- CABA United States
- Employees
- BMEA N/A
- CABA N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMEA Health Care
- CABA Health Care
- Exchange
- BMEA Nasdaq
- CABA Nasdaq
- Market Cap
- BMEA 145.0M
- CABA 118.8M
- IPO Year
- BMEA 2021
- CABA 2019
- Fundamental
- Price
- BMEA $3.46
- CABA $2.06
- Analyst Decision
- BMEA Buy
- CABA Strong Buy
- Analyst Count
- BMEA 13
- CABA 8
- Target Price
- BMEA $27.92
- CABA $26.13
- AVG Volume (30 Days)
- BMEA 414.8K
- CABA 1.4M
- Earning Date
- BMEA 03-31-2025
- CABA 03-20-2025
- Dividend Yield
- BMEA N/A
- CABA N/A
- EPS Growth
- BMEA N/A
- CABA N/A
- EPS
- BMEA N/A
- CABA N/A
- Revenue
- BMEA N/A
- CABA N/A
- Revenue This Year
- BMEA N/A
- CABA N/A
- Revenue Next Year
- BMEA N/A
- CABA N/A
- P/E Ratio
- BMEA N/A
- CABA N/A
- Revenue Growth
- BMEA N/A
- CABA N/A
- 52 Week Low
- BMEA $3.25
- CABA $1.76
- 52 Week High
- BMEA $19.36
- CABA $24.85
- Technical
- Relative Strength Index (RSI)
- BMEA 34.96
- CABA 38.28
- Support Level
- BMEA $3.25
- CABA $2.03
- Resistance Level
- BMEA $3.75
- CABA $2.90
- Average True Range (ATR)
- BMEA 0.24
- CABA 0.24
- MACD
- BMEA 0.00
- CABA -0.04
- Stochastic Oscillator
- BMEA 21.43
- CABA 4.00
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.